<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2381">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440007</url>
  </required_header>
  <id_info>
    <org_study_id>STI-5656-2001</org_study_id>
    <nct_id>NCT04440007</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19</brief_title>
  <acronym>SOC</acronym>
  <official_title>A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC&#xD;
      in subjects hospitalized with COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, randomized 2-arm multicenter study to assess the safety and&#xD;
      efficacy of STI-5656 (Abivertinib Maleate) administered orally plus Standard of Care (SOC)&#xD;
      versus SOC in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 infection and COVID-19&#xD;
      pneumonia (documented radiographically). Only hospitalized patients are eligible for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects alive and free of respiratory failure at Day 28</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Proportion of subjects alive and free of respiratory failure at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656)</measure>
    <time_frame>Randomization through study completion to 90 days</time_frame>
    <description>Types, frequencies, and severities of adverse events and their relationships to STI-5656</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects alive and free of respiratory failure at Day 60</measure>
    <time_frame>Randomization to Day 60</time_frame>
    <description>Proportion of subjects alive and free of respiratory failure at Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status</measure>
    <time_frame>Randomization to Day 7, Day 14, and Day 28</time_frame>
    <description>Change in clinical status on a 0-8-point ordinal scale (lower score means better outcome; 0=uninfected, 8=dead)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge from ICU</measure>
    <time_frame>Randomization to Day 14 and Day 28</time_frame>
    <description>Proportion of subjects alive and discharged from ICU at Days 14 and 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to respiratory failure or death</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Time from randomization to first occurrence of respiratory failure or death on study due to any cause up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Percent change from baseline in CRP at Days 3, 5, 7, 10, 14, 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in oxygenation index</measure>
    <time_frame>Randomization to Day 5</time_frame>
    <description>Relative change from baseline in PaO2/FiO2 up to Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at Day 60 and Day 90</measure>
    <time_frame>Ranomization through Day 90</time_frame>
    <description>All-cause mortality at Day 60 and Day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive and free of respiratory failure at Day 28</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Number of days alive and free of respiratory failure at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with respiratory failure up to Day 28</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Number of days with respiratory failure up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days hospitalized up to Day 28</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Number of days hospitalized up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in ICU (length of stay) up to Day 90</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Number of days in ICU (length of stay) up to Day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive outside of hospital up to Day 28</measure>
    <time_frame>Randomization to Day 28</time_frame>
    <description>Number of days alive outside of hospital up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive outside of hospital up to Day 90</measure>
    <time_frame>Randomization to Day 90</time_frame>
    <description>Number of days alive outside of hospital up to Day 90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Abivertinib with Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STI-5656 (abivertinib maleate) capsule administered orally 200 mg QD up to 28 days or until hospital discharge, in addition to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care treatments for COVID-19 as determined appropriate by the Investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abivertinib</intervention_name>
    <description>Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.</description>
    <arm_group_label>Abivertinib with Standard of Care</arm_group_label>
    <other_name>abivertinib maleate</other_name>
    <other_name>avitinib</other_name>
    <other_name>AC0010</other_name>
    <other_name>STI-5656</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care as determined by the Investigator</description>
    <arm_group_label>Abivertinib with Standard of Care</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed infection with SARS-CoV-2 per World Health Organization (WHO) criteria&#xD;
             (including positive RT-PCR nucleic acid test of any specimen [eg, respiratory, blood,&#xD;
             urine, stool, or other bodily fluid]) within 7 days of randomization&#xD;
&#xD;
          -  Hospitalized with COVID-19 pneumonia (documented radiographically) and oxygen&#xD;
             saturation &lt;94% on room air or subject requires supplemental oxygen&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  Willing to follow contraception guidelines&#xD;
&#xD;
          -  Subject or family member/caregiver must have provided written informed consent which&#xD;
             includes signing the institutional review board approved consent form prior to&#xD;
             participating in any study related activity. However, if obtaining written informed&#xD;
             consent is not possible, other procedures as provided in the March 27th, 2020 FDA&#xD;
             Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic,&#xD;
             Question 10, may be used&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known cardio-pulmonary resuscitation within 14 days prior to randomization&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides&#xD;
             infection with SARS-CoV-2)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) â‰¥ 3x upper limit of normal (ULN) and total bilirubin &gt;&#xD;
             2x ULN&#xD;
&#xD;
          -  QTcF prolongation &gt;480 milliseconds&#xD;
&#xD;
          -  Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the&#xD;
             last 6 weeks, or congestive heart failure (NYHA Grade 3 or 4). Exception: Subjects&#xD;
             with controlled, asymptomatic atrial fibrillation during screening are allowed to&#xD;
             enroll&#xD;
&#xD;
          -  Treatment with a strong cytochrome P450 (CYP3A4 inhibitor (within 14 days before first&#xD;
             dose of study drug) or inducer (within 7 days before first dose of study drug)&#xD;
&#xD;
          -  Received anti-rejection or immunomodulatory drugs (eg, anti-cytokines, BTK inhibitors,&#xD;
             JAK inhibitors, PI3K inhibitors) within 30 days before randomization on study&#xD;
&#xD;
          -  Concurrent participation in another clinical trial involving therapeutic interventions&#xD;
             (observational study participation is acceptable)&#xD;
&#xD;
          -  Any condition that confounds the ability to interpret data from the study&#xD;
&#xD;
          -  Relevant renal impairment (eGFR &lt;60 mL/min)&#xD;
&#xD;
          -  Any significant medical condition, laboratory abnormality or psychiatric illness that&#xD;
             would interfere or prevent the subject from participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD JD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Royal, MD JD</last_name>
    <phone>858-203-4100</phone>
    <email>mroyal@sorrentotherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Yan, MD MS</last_name>
    <phone>(858) 203-4183</phone>
    <email>yyan@sorrentotherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenn Wortmann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Glenn Wortmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Teradan Clinical Trials</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Lorch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Lorch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexandria Cardiology Clinic</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Dubois</last_name>
    </contact>
    <investigator>
      <last_name>Naseem Jaffrani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of SWLA</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Thompson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ben Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Hollis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brian Hollis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Memorial City Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Skolnick, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alan Skolnick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

